Update on liver transplantation using cyclosporine

Transplantation Proceedings

Volumn 36, Issue 9, 2004, Pages 2525-2531

  Schrem, H ^a   Luck R ^a   Becker, T ^a   Nashan, B ^a   Klempnauer, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BASILIXIMAB; CALCIUM ANTAGONIST; CERIVASTATIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; FLUINDOSTATIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MEVINOLIN; MIBEFRADIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEFAZODONE; PRAVASTATIN; SIMVASTATIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALOPECIA; AREA UNDER THE CURVE; BLINDNESS; BONE DENSITY; CEREBELLAR ATAXIA; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GINGIVA HYPERPLASIA; GRAFT REJECTION; GRAFT SURVIVAL; HALLUCINATION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOCHOLESTEROLEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOENCEPHALOPATHY; LIVER FAILURE; LIVER METABOLISM; LIVER REGENERATION; LIVER TRANSPLANTATION; LONG TERM CARE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MICROEMULSION; MOTOR DYSFUNCTION; MYOSITIS; NEPHROTOXICITY; NEURALGIA; NEUROLOGIC DISEASE; NEUROTOXICITY; OSTEOLYSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; SEIZURE; SURGICAL MORTALITY; TREMOR; WEIGHT GAIN;

EID: 11144350492     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.10.023     Document Type: Article

References (60)

1. J. Klempnauer, H. Schrem, T. Becker Liver transplantation today Transplant Proc 33 2001 3433
2. S.J. Provencher, C. Demers, M.C. Bastien Effect of cyclosporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat Drug Metab Dispos 27 1999 449
3. H. Schrem, J. Klempnauer, J. Borlak Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression Pharmacol Rev 54 2002 129
4. L.G. Alvira, N. Herrera, C. Salas Influence of cyclosporine on graft regeneration and function after liver transplantation: trial in pigs Transplant Proc 34 2002 315
5. A.R. Mueller, K.P. Platz, G. Blumhardt The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Clin Transplant 9 1995 176
6. G.T. Everson Impact of immunosuppressive therapy on recurrence of hepatitis C Liver Transpl 8 10 suppl 1 2002 S19
7. R.D. Gordon, B.W. Jr Shaw, S. Iwatsuki Indications for liver transplantation in the cyclosporine era Surg Clin North Am 66 1986 541
8. R.Y. Calne Cyclosporine and liver transplantation Mt Sinai. J Med 54 1987 465
9. T.E. Starzl, S. Iwatsuki, B.W. Jr Shaw Liver transplantation in the ciclosporin era Prog Allergy 38 1986 366
10. A.W. Thomson, C.A. Bonham, A. Zeevi Mode of action of tacrolimus (FK506): molecular and cellular mechanisms Ther Drug Monit 17 1995 584
11. M.L. Henry Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles Clin Transplant 13 1999 209
12. C.J. Dunn, A.J. Wagstaff, C.M. Perry Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation Drugs 61 2001 1957
13. K.A. Jorgensen, P.B. Koefoed-Nielsen, N. Karamperis Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus Scand J Immunol 57 2003 93
14. C.S. Hemenway, J. Heitman Calcineurin. Structure, function, and inhibition Cell Biochem Biophys 30 1999 115
15. L. Mascarell, P. Truffa-Bachi New aspects of cyclosporin a mode of action: from gene silencing to gene up-regulation Mini Rev Med Chem 3 2003 205
16. J.R. Blankenship, W.J. Steinbach, J.R. Perfect Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs Curr Opin Investig Drugs 4 2003 192
17. U. Frei Overview of the clinical experience with Neoral in transplantation Transplant Proc 31 1999 1669
18. M.B. Shah, J.E. Martin, T.J. Schroeder The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis Transplantation 67 1999 1411
19. F.K.506 Multicentre Liver Study Group European Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection Lancet 344 1994 423
20. U.S. Multicenter F.K.506 Liver Study Group The A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1994 1110
21. T.E. Starzl, S. Todo, A.J. Demetris Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet Am J Kidney Dis 31 6 suppl 1 1998 S7
22. W. Timmermann, J. Erhard, R. Lange A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation Transplant Proc 34 2002 1516
23. S.P. Dunn Neoral monitoring 2 hours post-dose and the pediatric transplant patient Pediatr Transplant 7 2003 25
24. G. Levy, P. Burra, A. Cavallari Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2) Transplantation 73 2002 953
25. A. Jain, J. Reyes, R. Kashyap Long-term survival after liver transplantation in 4,000 consecutive patients at a single center Ann Surg 232 2000 490
26. Cid T. Parra, Garcia J.R. Conejo, Alvarez F. Carballo Antioxidant nutrients protect against cyclosporine A nephrotoxicity Toxicology 189 2003 99
27. O. Oettinger-Barak, E.E. Machtei, M. Peled Cyclosporine A- induced gingival hyperplasia pemphigus vulgaris: literature review and report of a case J Periodontol 71 2000 650
28. P. Marchetti, R. Navalesi The metabolic effects of cyclosporin and tacrolimus J Endocrinol Invest 23 2000 482
29. V.M. Montori, A. Basu, P.J. Erwin Posttransplantation diabetes: a systematic review of the literature Diabetes Care 25 2002 583
30. J.M. Gijtenbeek, den Bent M.J. van, C.J. Vecht Cyclosporine neurotoxicity: a review J Neurol 246 1999 339
31. W.O. Bechstein Neurotoxicity of calcineurin inhibitors: impact and clinical management Transpl Int 13 2000 313
32. E.F. Wijdicks Neurotoxicity of immunosuppressive drugs Liver Transpl 7 2001 937
33. H.J. Schlitt, A. Barkmann, K.H. Boker Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587
34. J.P. Lerut, O. Ciccarelli, E. Mauel Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study Transpl Int 14 2001 420
35. K. Rolles, B.R. Davidson, A.K. Burroughs A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin Transplantation 68 1999 1195
36. A. Asberg Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients Drugs 63 2003 367
37. R. Paoletti, A. Corsini, S. Bellosta Pharmacological interactions of statins Atheroscler Suppl 3 2002 35
38. P.J. Gruer, J.M. Vega, M.F. Mercuri Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin Am J Cardiol 84 1999 811
39. M. Lassila Interaction of cyclosporine A and the renin-angiotensin system; new perspectives Curr Drug Metab 3 2002 61
40. T. Breidenbach, M.W. Hoffmann, T. Becker Drug interaction of St John's wort with cyclosporin Lancet 355 2000 1912
41. S.M. Tsunoda, R.Z. Harris, U. Christians Red wine decreases cyclosporine bioavailability Clin Pharmacol Ther 70 2001 462
42. S. Bauer, E. Stormer, A. Johne Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients Br J Clin Pharmacol 55 2003 203
43. M. Hermann, A. Asberg, J.L. Reubsaet Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients Int J Clin Pharmacol Ther 40 2002 451
44. P.F. Halloran, L.M. Helms, L. Kung The temporal profile of calcineurin inhibition by cyclosporine in vivo Transplantation 68 1999 1356
45. K. Wonigeit, K. Kohlhaw, M. Winkler Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity Transplant Proc 22 1990 1305
46. P.A. Keown New concepts in cyclosporine monitoring Curr Opin Nephrol Hypertens 11 2002 619
47. B.D. Kahan, P. Keown, G.A. Levy Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 2002 330
48. G.A. Levy New strategies to optimize clinical outcomes with cyclosporine in liver transplantation Gastroenterol Hepatol 25 2002 289
49. B. Nashan, E. Cole, G. Levy Clinical validation studies of Neoral C(2) monitoring: a review Transplantation 73 9 suppl 2002 S3
50. G. Levy, E. Thervet, J. Lake Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group (2002). Patient management by Neoral C(2) monitoring: an international consensus statement Transplantation 73 9 suppl 2002 S12
51. D.A. Kelly Strategies for optimizing immunosuppression in adolescent transplant recipients: a focus on liver transplantation Paediatr Drugs 5 2003 177
52. G.V. Mazariegos, A.A. Salzedas, A. Jain Conversion from cyclosporin to tacrolimus in pediatric liver transplant recipients Paediatr Drugs 3 2001 661
53. G.F. Cooney, S.P. Dunn, J. Sommerauer Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation Liver Transplant Surg 5 1999 112
54. S. Dunn, K. Falkenstein, G. Cooney Neoral C2 monitoring in pediatric liver transplant recipients Transplant Proc 33 2001 3094
55. A. Tendron, J.B. Gouyon, S. Decramer In utero exposure to immunosuppressive drugs: experimental and clinical studies Pediatr Nephrol 17 2002 121
56. A. Prevot, S. Martini, J.P. Guignard In utero exposure to immunosuppressive drugs Biol Neonate 81 2002 73
57. Oz B. Bar, R. Hackman, T. Einarson Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis Transplantation 71 2001 1051
58. B. Nashan Early clinical experience with a novel rapamycin derivative Ther Drug Monit 24 2002 53
59. B. Nashan Review of the proliferation inhibitor everolimus Expert Opin Investig Drugs 11 2002 1845
60. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847